Prior to founding Viscient, Keith co-founded Organovo in 2007 and led all company operations until 2017. He co-invented Organovo’s NovoGen MMX bioprinter platform (one of TIME magazine’s “Best Inventions of 2010”) and grew Organovo through early investments and corporate partnerships, including major alliances with Astellas and Merck. Prior to Organovo, Keith spent 10 years at Amgen, including four years as the Global Operations Leader of denosumab (Prolia and Xgeva). Keith serves on the board of CLSA and Adgero Biopharmaceuticals.
.svg)
